Bristol Myers Squibb: ahead of almost everyone like it.
- Industry
- Pharmaceutical Preparations Manufacturing
- Headquarters
- United States
- Ticker
- BMY (NYSE)
- Sources
- SEC filings (1994–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
- Data as of
- November 15, 2026
- Ahead of almost everyone like it. From 2016 to 2025, its revenue grew 148% in US dollars; the median among 181 large manufacturers grew 49%. It outgrew 84% of them.
- Leaders came and went. Bristol Myers Squibb filed 37 leadership changes since 2016, more than 89% of large manufacturers (the median is 20). The day after each, its shares moved a median 0.0 points against its sector. The news was rarely news.
- One decision on record. Stratrix has verified one of Bristol Myers Squibb's big decisions, each with what happened next.
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | $19.4 billion | $4.5 billion | |
| 2017 | $20.8 billion | $1 billion | |
| 2018 | $22.6 billion | $4.9 billion | |
| 2019 | $26.1 billion | $3.4 billion | |
| 2020 | $42.5 billion | −$9 billion | |
| 2021 | $46.4 billion | $7 billion | |
| 2022 | $46.2 billion | $6.3 billion | |
| 2023 | $45 billion | $8 billion | |
| 2024 | $48.3 billion | −$8.9 billion | |
| 2025 | $48.2 billion | $7.1 billion |
As reported in its annual filings. Losses in red.
Stratrix Decision Cases
Has Bristol Myers Squibb had layoffs?
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | approximately 34,100 | December 31, 2023 |
| 10-K for 2024 | approximately 34,100 | As of December 31, 2024 |
| 10-K for 2025 | approximately 32,500 | December 31, 2025 |
Job cuts, severance and restructuring
The company recorded a new restructuring plan in 2023, with provision for restructuring of $365 million in other (income)/expense.
“Provision for restructuring includes exit and other costs primarily related to certain restructuring activities including a new plan in 2023 discussed further in "Item 8. Financial Statements and Supplementary Data—Note 6. Restructuring."” 10-K for 2023
| Fiscal year ended | Severance costs | Restructuring charges | Cash paid for restructuring |
|---|---|---|---|
| 2016-12-31 | $97 million | $109 million | $120 million |
| 2017-12-31 | $267 million | $293 million | $239 million |
| 2018-12-31 | $87 million | $131 million | $219 million |
| 2019-12-31 | $273 million | $301 million | $151 million |
| 2020-12-31 | $457 million | $530 million | $418 million |
| 2021-12-31 | $159 million | $169 million | $199 million |
| 2022-12-31 | $69 million | $75 million | $122 million |
| 2023-12-31 | $350 million | $365 million | $225 million |
| 2024-12-31 | $623 million | $635 million | $520 million |
| 2025-12-31 | $548 million | $563 million | $558 million |
Bristol Myers Squibb has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
What has Bristol Myers Squibb acquired?
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Mirati“(i) the acquisition of Mirati, which was completed in January 2024; (ii) the planned acquisitions of Karuna and RayzeBio, which were announced in December 2023; and (iii) a global strategic collaboration agreement with SystImmune, which was announced in December 2023.” 10-K for 2023 | acquisition | completed in January 2024 | — |
Karuna“(ii) the planned acquisitions of Karuna and RayzeBio, which were announced in December 2023; and (iii) a global strategic collaboration agreement with SystImmune, which was announced in December 2023.” 10-K for 2023 | agreed acquisition | announced in December 2023 | — |
RayzeBio“(ii) the planned acquisitions of Karuna and RayzeBio, which were announced in December 2023; and (iii) a global strategic collaboration agreement with SystImmune, which was announced in December 2023.” 10-K for 2023 | agreed acquisition | announced in December 2023 | — |
Turning Point“partially offset by the acquisition of Turning Point ($3.2 billion net of cash acquired) in 2022.” 10-K for 2023 | acquisition | 2022 | $3.2 billion net of cash acquired |
Mavacamten rights buy-out“Mavacamten rights buy-out (Note 4) $ 445 $ — Orum upfront payment (Note 4) 100 — Mavacamten royalty extinguishment (Note 4) — 295 Dragonfly milestone and opt-in license fee — 200 Evotec designation and opt-in license fees 90 — BridgeBio upfront collaboration fee — 90 Prothena opt-in license fee 55 Zenas upfront license fee 50 — Immatics upfront license and opt-in fee (Note 4) 15 150 Other 158 80 Acquired IPRD $ 913 $ 815 Refer to “Item 8. Financial Statements and Supplementary Data—Note 3. Alliances” and “—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements” for additional information.” 10-K for 2023 | acquisition | — | — |
diabetes business“Royalties have continued to represent a significant percentage of our pretax income, including royalties related to the divestiture of our diabetes business (including the transfer of certain future royalty rights pertaining to Amylin, Onglyza* and Farxiga* product sales), out-licensed intellectual property and the Merck patent infringement settlement.” 10-K for 2023 | divestiture | — | — |
SystImmune“We also entered into a strategic collaboration with SystImmune, to co-develop and co-commercialize izalontamab brengitecan (iza-bren or BL-B01D1), a bispecific topoisomerase inhibitor-based anti-body drug conjugate.” 10-K for 2024 | agreed acquisition | — | — |
Orbital Therapeutics“In 2025, the Company (i) acquired Orbital Therapeutics, which provided the Company with full rights to OTX-201, a preclinical in vivo CAR T-cell therapy currently in IND-enabling studies for autoimmune disease, (ii) entered into a strategic collaboration with BioNTech to co-develop and co-commercialize BioNTech's investigational bispecific antibody pumitamig (BNT327/BMS986545) across multiple solid tumor types, (iii) acquired a global exclusive license from Philochem for OncoACP3, a radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer, and (iv) expanded our development and manufacturing capabilities by opening a new radiopharmaceutical facility in Indianapolis, Indiana, which will support RPTs acquired in connection with the RayzeBio acquisition.” 10-K for 2025 | acquisition | 2025 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2016-12-31 | $359 million | — |
| 2017-12-31 | $726 million | — |
| 2018-12-31 | $2.37 billion | — |
| 2019-12-31 | $24.78 billion | — |
| 2020-12-31 | $13.08 billion | — |
| 2021-12-31 | $1.61 billion | — |
| 2022-12-31 | $4.29 billion | — |
| 2023-12-31 | $1.17 billion | $0 |
| 2024-12-31 | $21.82 billion | $580 million |
| 2025-12-31 | $3.94 billion | $0 |
Deal filings since 2016
- 2022-03-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-02-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-11-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-11-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-02-05 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2019-11-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-11-22 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2019-11-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-11-20 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2019-05-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-01-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-01-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-01-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Who are Bristol Myers Squibb's competitors?
Who Bristol Myers Squibb names
Bristol Myers Squibb’s annual reports for 2023 to 2025 describe its competition by kind of business and do not name competing companies.
Who names Bristol Myers Squibb
Companies whose own annual reports name Bristol Myers Squibb as a competitor.
“Bristol Myers Squibb OPDIVO U.S., Europe, Asia Pacific & China” 10-K for 2025
“Bristol-Myers Squibb's anti-CD19 CAR-T therapy, Breyanzi ("liso-cel"), as well as anti-BCMA CAR-T therapy, Abecma ("ide-cel"), in collaboration with bluebird bio, are also marketed CAR-T products.” 20-F for 2025
“There are several competitors that are marketing and/or developing antibodies against PD-1 and/or PDL-1 (some of which were approved in the relevant indications and commercialized before Libtayo), including Merck's Keytruda ® (pembrolizumab), Bristol-Myers Squibb's Opdivo ® (nivolumab), Roche's Tecentriq ® (atezolizumab), AstraZeneca's Imfinzi ® (durvalumab), and Sun Pharma's Unloxcyt ™ (cosibelimab).” 10-K for 2025
“Bristol-Myers Squibb's, or BMS's nivolumab and Merck's pembrolizumab are approved for the treatment of certain patients with relapsed or refractory classical Hodgkin lymphoma, and Acrotech Biopharma's pralatrexate and belinostat are approved for relapsed or refractory systemic anaplastic large cell lymphoma, or sALCL, among other T-cell lymphomas.” 10-K for 2022
What are Bristol Myers Squibb's subsidiaries?
Subsidiaries it lists
| Subsidiary | Jurisdiction |
|---|---|
| 1096271 BC ULC | Canada |
| 2seventy bio, Inc | United States |
| 2seventy bio Securities Corporation | United States |
| 345 Park LLC | United States |
| 9643435 Canada Inc. | Canada |
| Abraxis BioScience Australia Pty Ltd. | Australia |
| Abraxis BioScience International Holding Company, Inc. | United States |
| Abraxis BioScience, Inc. | United States |
| Abraxis BioScience, LLC | United States |
| AbVitro LLC | United States |
| Adnexus, a Bristol-Myers Squibb R&D Company | United States |
| AHI Investment, LLC | United States |
| Allard Labs Acquisition G.P. | United States |
| Amira Pharmaceuticals, Inc. | United States |
| Apothecon LLC | United States |
| Blisa Acquisition G.P. | United States |
| BMS Bermuda Nominees L.L.C. | United States |
| BMS Forex Company | United States |
| BMS Holdings Netherlands Beta B.V. | Netherlands |
| BMS Ireland Capital Funding Designated Activity Company | Ireland |
| BMS Korea Holdings L.L.C. | United States |
| BMS Latin American Nominees L.L.C. | United States |
| BMS Netherlands Operations B.V. | Netherlands |
| BMS Pharmaceutical Korea Limited | Korea, Republic of |
| BMS Pharmaceuticals Germany Holdings B.V. | Netherlands |
| BMS Pharmaceuticals International Holdings Netherlands B.V. | Netherlands |
| BMS Pharmaceuticals Korea Holdings B.V. | Netherlands |
| BMS Pharmaceuticals Mexico Holdings B.V. | Netherlands |
| BMS Pharmaceuticals Netherlands Holdings B.V. | Netherlands |
| BMS Real Estate LLC | United States |
| BMS Spain Investments LLC | United States |
| BMS Strategic Portfolio Investments Holdings, Inc. | United States |
| Bristol Laboratories International, S.A. | United States |
| Bristol Laboratories Medical Information Systems Inc. | United States |
| Bristol-Myers (Andes) L.L.C. | United States |
| Bristol-Myers Squibb (Beijing) Innovation Pharmaceutical Technology Co., Ltd. | China |
| Bristol-Myers (Private) Limited | Zimbabwe |
| Bristol-Myers Overseas Corporation | United States |
| Bristol-Myers Squibb (China) Investment Co., Ltd. | China |
| Bristol-Myers Squibb (China) Pharmaceuticals Co., Ltd. | China |
| Bristol-Myers Squibb (Israel) Ltd. | Israel |
| Bristol-Myers Squibb (NZ) Limited | New Zealand |
| Bristol-Myers Squibb (Proprietary) Limited | South Africa |
| Bristol-Myers Squibb (Shanghai) Trading Co. Ltd. | China |
| Bristol-Myers Squibb (Singapore) Pte. Limited | Singapore |
| Bristol-Myers Squibb (Taiwan) Ltd. | Taiwan Province of China |
| Bristol-Myers Squibb (West Indies) Ltd. | United States |
| Bristol-Myers Squibb A.E. | Greece |
| Bristol-Myers Squibb Aktiebolag | Sweden |
| Bristol-Myers Squibb Argentina S. R. L. | Argentina |
| Bristol-Myers Squibb Australia Pty. Ltd. | Australia |
| Bristol-Myers Squibb B.V. | Netherlands |
| Bristol-Myers Squibb Belgium S.A. | Belgium |
| Bristol-Myers Squibb Business Services India Private Limited | India |
| Bristol-Myers Squibb Business Services Limited | United Kingdom |
| Bristol-Myers Squibb Canada Co. | Canada |
| Bristol-Myers Squibb Canada International Limited | Canada |
| Bristol-Myers Squibb de Colombia S.A. | Colombia |
| Bristol-Myers Squibb de Mexico, S. de R.L. de C.V. | Mexico |
| Bristol-Myers Squibb Delta Company Limited | Ireland |
| Bristol-Myers Squibb Denmark Filial of Bristol-Myers Squibb AB | Denmark |
| Bristol-Myers Squibb Egypt, LLC | Egypt |
| Bristol-Myers Squibb EMEA Sarl | France |
| Bristol-Myers Squibb Epsilon Holdings Unlimited Company | Ireland |
| Bristol-Myers Squibb Farmaceutica Ltda. | Brazil |
| Bristol-Myers Squibb Farmaceutica Portuguesa S.A. | Portugal |
| Bristol-Myers Squibb Ges mbH. | Austria |
| Bristol-Myers Squibb GmbH & Co. KGaA | Germany |
| Bristol-Myers Squibb Hanbai K.K | Japan |
| Bristol-Myers Squibb Holding Germany GmbH & Co. KG | Germany |
| Bristol-Myers Squibb Holdings 2002 Limited | United Kingdom |
| Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH | Germany |
| Bristol-Myers Squibb Holdings Ireland Unlimited Company | Ireland |
| Bristol-Myers Squibb Holdings Limited | United Kingdom |
| Bristol-Myers Squibb Holdings Pharma Ltd. Liability Company | Switzerland |
| Bristol-Myers Squibb Ilaclari, Inc. | United States |
| Bristol-Myers Squibb India Pvt. Limited | India |
| Bristol-Myers Squibb International Company Unlimited Company | Ireland |
| Bristol-Myers Squibb International Corporation | United States |
| Bristol-Myers Squibb Investco, L.L.C. | United States |
| Bristol-Myers Squibb K.K. | Japan |
| Bristol-Myers Squibb Kft. | Hungary |
| Bristol-Myers Squibb Limited Liability Company | Russian Federation |
| Bristol-Myers Squibb Manufacturing Company Unlimited Company | Ireland |
| Bristol-Myers Squibb Marketing Services S.R.L. | Romania |
| Bristol-Myers Squibb MEA GmbH | Switzerland |
| Bristol-Myers Squibb Middle East & Africa FZ-LLC | United Arab Emirates |
| Bristol-Myers Squibb Norway Holdings Inc. | United States |
| Bristol-Myers Squibb Norway AS | Norway |
| Bristol-Myers Squibb Peru S.A. | Peru |
| Bristol-Myers Squibb Pharma (HK) Ltd | Hong Kong |
| Bristol-Myers Squibb Pharma (Thailand) Limited | Thailand |
| Bristol-Myers Squibb Pharma Company | United States |
| Bristol-Myers Squibb Pharma EEIG | Ireland |
| Bristol-Myers Squibb Pharma Holding Company, LLC | United States |
| Bristol-Myers Squibb Pharma Ventures Corporation | United States |
| Bristol-Myers Squibb Pharmaceuticals Limited | United Kingdom |
| Bristol-Myers Squibb Pharmaceuticals Unlimited Company | Ireland |
| Bristol-Myers Squibb Polska Sp. z o.o. | Poland |
| Bristol-Myers Squibb Products S.A. | Switzerland |
| Bristol-Myers Squibb Puerto Rico, Inc. | United States |
| Bristol Myers Squibb Regional Headquarter Company | Saudi Arabia |
| Bristol-Myers Squibb Romania S.R.L. | Romania |
| Bristol-Myers Squibb S.r.l. | Italy |
| Bristol-Myers Squibb SA | Switzerland |
| Bristol-Myers Squibb SAS | France |
| Bristol-Myers Squibb Service Ltd. | Bermuda |
| Bristol-Myers Squibb Services Sp. z o.o. | Poland |
| Bristol-Myers Squibb Services Unlimited Company | Ireland |
| Bristol-Myers Squibb Spol. s r.o. | Czech Republic |
| Bristol-Myers Squibb TGF Beta Inc. | Canada |
| Bristol-Myers Squibb Trustees Ltd. | United Kingdom |
| Bristol-Myers Squibb Verwaltungs GmbH | Germany |
| Bristol-Myers Squibb, S.A.U. | Spain |
| Bristol-Myers Squibb/Astrazeneca EEIG | United Kingdom |
| Bristol-Myers Squibb/Pfizer EEIG | Ireland |
| Cardioxyl Pharmaceuticals, LLC | United States |
| Celgene CAR LLC | United States |
| Celgene Chemicals Sarl | Switzerland |
| Celgene China Holdings LLC | United States |
| Celgene Corporation | United States |
| Celgene d.o.o. | Croatia |
| Celgene Distribution B.V. | Netherlands |
| Celgene Europe B.V. | Netherlands |
| Celgene Europe Limited | United Kingdom |
| Celgene Financing Company, LLC | United States |
| Celgene Global Holdings Sarl | Switzerland |
| Celgene Holdings East Corporation | United States |
| Celgene International Holdings Corporation | United States |
| Celgene International Holdings Corporation, Prodruznica v Sloveniji | Slovenia |
| Celgene International II Sàrl | Switzerland |
| Celgene International Inc. | United States |
| Celgene International Sàrl | Switzerland |
| Celgene Kappa Holdings LLC | United States |
| Celgene Limited | Hong Kong |
| Celgene Limited | Ireland |
| Celgene Limited | Taiwan Province of China |
| Celgene Limited | United Kingdom |
| Celgene Logistics Sarl | Switzerland |
| Celgene Logistics Sarl (Sucursale Mexico) | Mexico |
| Celgene Netherlands BV | Netherlands |
| Celgene Netherlands Investment BV | Netherlands |
| Celgene NJ Investment Co | United States |
| Celgene Omicron Holdings, Inc. | United States |
| Celgene Pharmaceutical (Shanghai) Company Limited | China |
| Celgene Pty Limited | Australia |
| Celgene Puerto Rico Distribution LLC | Puerto Rico |
| Celgene Quanticel Research, Inc. | United States |
| Celgene R&D Sarl | Switzerland |
| Celgene Receptos Limited | United Kingdom |
The list is long; these are the first 150 as the company lists them. From Exhibit 21 of the 10-K for 2025. Companies must list their significant subsidiaries there and may leave out smaller ones, so this is the company’s own list, not every entity it owns.
Layoffs, acquisitions, competitors and subsidiaries are read from Bristol Myers Squibb’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023), as of 2026-02-11.
Everything behind these findings, ready for your board deck.
- Market reaction to disclosed decisions: 53 decision filings since 2016, each linked to the SEC, with the share return against its sector and the US market the next day and the next year (39 with market data).
- Economic context: 7 measures for the United States, every year since 2016, from the official sources.
- Peer comparison: against 264 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.
Tools to try
- Ansoff move finderFramework: Ansoff Matrix
- Business model canvas builderFramework: Business Model Canvas
- Change readiness checkFramework: Kotter's 8-Step Change Model
- Five Forces scorerFramework: Porter's Five Forces
- SMART goal builderFramework: SMART Goals
- SWOT builderFramework: SWOT Analysis
More from Stratrix
The Business Model Wizard
Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.
Free · about twelve minutesBuild your Model Thesis →Test a decision, free
Set a live decision against the companies that made it before you.
AcquisitionsThe Distance TestDivestituresThe Divestiture TestDiversificationThe Diversification TestMake or buyThe Make-or-Buy TestWeekly email
Stratonomics, every Tuesday
One data story every Tuesday: what happened, what it means, and the figures you can quote. Free.